272 related articles for article (PubMed ID: 17393785)
1. [Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction].
Zhang SX; Gao P
Zhonghua Nan Ke Xue; 2007 Mar; 13(3):226-8. PubMed ID: 17393785
[TBL] [Abstract][Full Text] [Related]
2. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Gresser U; Gleiter CH
Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
Berner MM; Kriston L; Harms A
Int J Impot Res; 2006; 18(3):229-35. PubMed ID: 16239897
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
Chen Q; Wang N; Yao F; Lu X
Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
[TBL] [Abstract][Full Text] [Related]
5. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
[TBL] [Abstract][Full Text] [Related]
7. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F
Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
[TBL] [Abstract][Full Text] [Related]
8. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
9. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
Doggrell S
Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
[TBL] [Abstract][Full Text] [Related]
10. [Impact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse interval].
Giuliano F; Vicaut E; Jeanpetit Y
Prog Urol; 2008 Sep; 18(8):536-42. PubMed ID: 18760744
[TBL] [Abstract][Full Text] [Related]
11. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release.
Toque HA; Priviero FB; Teixeira CE; Claudino MA; Baracat JS; Fregonesi A; De Nucci G; Antunes E
Urology; 2009 Jul; 74(1):216-21. PubMed ID: 19371941
[TBL] [Abstract][Full Text] [Related]
12. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
Wright PJ
Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
14. Patients' preference in the treatment of erectile dysfunction: a critical review of the literature.
Morales AM; Casillas M; Turbi C
Int J Impot Res; 2011; 23(1):1-8. PubMed ID: 21191396
[TBL] [Abstract][Full Text] [Related]
15. Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction.
Brisson TE; Broderick GA; Thiel DD; Heckman MG; Pinkstaff DM
Urology; 2006 Aug; 68(2):397-401. PubMed ID: 16904460
[TBL] [Abstract][Full Text] [Related]
16. [Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours].
Deng SM
Zhonghua Nan Ke Xue; 2008 Sep; 14(9):857-60. PubMed ID: 18998474
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
Wong P; Lawrentschuk N; Bolton DM
Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
Gales BJ; Gales MA
Ann Pharmacother; 2008 Jan; 42(1):111-5. PubMed ID: 18094344
[TBL] [Abstract][Full Text] [Related]
19. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
Ströberg P; Hedelin H; Ljunggren C
Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
[TBL] [Abstract][Full Text] [Related]
20. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Kapur V; Chien CV; Fuess JE; Schwarz ER
Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
